MedPath

Residual effects of zopiclone 7.5 mg and temazepam 20 mg on cognition and actual driving performance in healthy elderly

Phase 1
Conditions
Healthy elderly volunteers
Registration Number
EUCTR2006-004305-25-NL
Lead Sponsor
Maastricht University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
18
Inclusion Criteria

1. Age between 55 and 75 years
2. Good health, in the opinion of the medical supervisor, on the basis of a pre-study physical examination, medical history, vital signs, electrocardiogram, and the results of blood biochemistry, haematology, and serology tests, and urinalysis.
3. Possession of a valid driving licence for 3 years or more
4. Driving experience of at least 3000 km per year on average

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. History of drug or alcohol abuse
2. BMI over 30 kg/m2
3. Chronic use of medication that affects driving performance
4. Smoking more than 10 cigarettes per day
5. Drinking more than 6 cups of coffee per day
6. Drinking more than 21 glasses of alcohol per week

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To assess the residual effects of zopiclone 7.5 mg and temazepam 20 mg on actual driving in healthy elderly volunteers.;Secondary Objective: To compare the residual effects of zopiclone 7.5 mg with those in young volunteers, as found recently in a study using the same tests and procedures (Leufkens & Vermeeren, in prep).;Primary end point(s): Standard Deviation of Lateral Position (SDLP in cm) in the highway driving test. SDLP is a measure of road tracking error; in practical terms, it is a composite index of allowed weaving, swerving, and overcorrecting.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath